First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

A. Hagenbeek; O. Gadeberg; P. Johnson; L.M. Pedersen; J. Walewski; A. Hellmann; B.K. Link; T. Robak; M. Wojtukiewicz; M. Pfreundschuh; M. Kneba; A. Engert; P. Sonneveld; M. Flensburg; J. Petersen; N. Losic; J. Radford

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

Translated title of the contribution: First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

A. Hagenbeek
, O. Gadeberg
, P. Johnson
, L.M. Pedersen
, J. Walewski
, A. Hellmann
, B.K. Link
, T. Robak
, M. Wojtukiewicz
, M. Pfreundschuh
, M. Kneba
, A. Engert
, P. Sonneveld
, M. Flensburg
, J. Petersen
, N. Losic
, J. Radford

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Original language	Undefined/Unknown
Pages (from-to)	5486-5495
Number of pages	10
Journal	Blood
Volume	111
Issue number	12
Publication status	Published - 2008

Cite this

Hagenbeek, A., Gadeberg, O., Johnson, P., Pedersen, L. M., Walewski, J., Hellmann, A., Link, B. K., Robak, T., Wojtukiewicz, M., Pfreundschuh, M., Kneba, M., Engert, A., Sonneveld, P., Flensburg, M., Petersen, J., Losic, N., & Radford, J. (2008). First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 111(12), 5486-5495.

@article{54b14c88a9df4180a6c28fa5cdd6576d,

title = "First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.",

author = "A. Hagenbeek and O. Gadeberg and P. Johnson and L.M. Pedersen and J. Walewski and A. Hellmann and B.K. Link and T. Robak and M. Wojtukiewicz and M. Pfreundschuh and M. Kneba and A. Engert and P. Sonneveld and M. Flensburg and J. Petersen and N. Losic and J. Radford",

year = "2008",

language = "Undefined/Unknown",

volume = "111",

pages = "5486--5495",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "12",

}

Hagenbeek, A, Gadeberg, O, Johnson, P, Pedersen, LM, Walewski, J, Hellmann, A, Link, BK, Robak, T, Wojtukiewicz, M, Pfreundschuh, M, Kneba, M, Engert, A, Sonneveld, P, Flensburg, M, Petersen, J, Losic, N & Radford, J 2008, 'First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.', Blood, vol. 111, no. 12, pp. 5486-5495.

TY - JOUR

T1 - First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

AU - Hagenbeek, A.

AU - Gadeberg, O.

AU - Johnson, P.

AU - Pedersen, L.M.

AU - Walewski, J.

AU - Hellmann, A.

AU - Link, B.K.

AU - Robak, T.

AU - Wojtukiewicz, M.

AU - Pfreundschuh, M.

AU - Kneba, M.

AU - Engert, A.

AU - Sonneveld, P.

AU - Flensburg, M.

AU - Petersen, J.

AU - Losic, N.

AU - Radford, J.

PY - 2008

Y1 - 2008

M3 - Article

SN - 0006-4971

VL - 111

SP - 5486

EP - 5495

JO - Blood

JF - Blood

IS - 12

ER -